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Abstract Receptor mediated endocytosis (RME) plays a major role in the dispo-
sition of therapeutic protein drugs in the body. It is suspected to be a major source of
nonlinear pharmacokinetic behavior observed in clinical pharmacokinetic data. So
far, mostly empirical or semi-mechanistic approaches have been used to represent
RME. A thorough understanding of the impact of the properties of the drug and of the
receptor system on the resulting nonlinear disposition is still missing, as is how to
best represent RME in pharmacokinetic models. In this article, we present a detailed
mechanistic model of RME that explicitly takes into account receptor binding and
trafﬁcking inside the cell and that is used to derive reduced models of RME which
retain a mechanistic interpretation. We ﬁnd that RME can be described by an
extended Michaelis–Menten model that accounts for both the distribution and the
elimination aspect of RME. If the amount of drug in the receptor system is negligible
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DOI 10.1007/s10928-009-9120-1a standard Michaelis–Menten model is capable of describing the elimination by
RME. Notably, a receptor system can efﬁciently eliminate drug from the extracel-
lular space even if the total number of receptors is small. We ﬁnd that drug elimi-
nation by RME can result in substantial nonlinear pharmacokinetics. The extent of
nonlinearity is higher for drug/receptor systems with higher receptor availability at
the membrane, or faster internalization and degradation of extracellular drug. Our
approach is exempliﬁed for the epidermal growth factor receptor system.
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Introduction
In recent years, therapeutic proteins have been a major focus of research and
development activities in the pharmaceutical industry [1]. Currently, approximately
100 therapeutic proteins have been approved for human use, most of them being
biotechnology-derived drug products and many more are under development.
Important classes of therapeutic proteins are monoclonal antibodies, growth factors,
andcytokines.Generally,therapeuticproteinsprovidehighlyattractivebutsometimes
exceptional behavior in the body [2]: their signiﬁcant therapeutic potential results
from their ability to bind—with high afﬁnity—to speciﬁc targets such as receptors or
cellsurfaceproteins.Formanyproteindrugsreceptormediatedendocytosis(RME)is
animportantrouteofcellularuptakeanddisposition[3].RMEistheprocessofbinding
of an endogenous or exogenous ligand to a receptor and subsequent internalization of
the resulting complex forming an endosome. Within the cell, the complex may be
recycled to the cell surface or intracellularly be cleaved [4, 5]. Receptor-mediated
uptake plays a major role in the elimination of protein drugs from the body [3] and is
suspectedtobeamajorsourceforthenonlinearpharmacokinetic(PK)behaviorthatis
observed in clinical data for numerous protein drugs [6].
Whenaimingatanalyzingpreclinical/clinicalpharmacokineticdataofproteindrug
trials, typically empirical 1-, 2- or 3-compartmental models including linear and/or
nonlinear disposition processes have been developed. Michaelis–Menten terms have
often been used to analyze experimental data in order to account for the observed
nonlinearity [7–11]. These models have been selected based on, e.g., established
statistical criteria (such as maximum likelihood), the precision of estimates of model
parameters, and in few cases on model evaluation techniques [12–15]. However,
beingempiricalinnature,thesemodelsdonotprovideamechanisticunderstandingof
how the different processes of receptor trafﬁcking contribute to the overall
pharmacokinetic proﬁle, which is expected to guide, e.g., lead optimization or the
design of more efﬁcient dosing regimens. Equally important, there is no theoretical
background as to when use the different existing empirical models for nonlinearity.
Less often, models have been developed that also include mechanistic terms to
account for nonlinear phenomena, most prominently in terms of target-mediated
drug disposition (TMDD) models [16–18]. TMDD explicitly accounts for binding to
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developed to describe effects of extensive drug target binding in tissues, TMDD has
more recently gained interest as a model for saturable elimination mechanisms for
speciﬁc peptide and protein drugs, including RME [6, 18, 19]. TMDD is a general
approach for situations where the interaction of a drug with its target is considered
to be relevant and might affect the concentration-time proﬁles. However, it does not
explicitly take into account the particular features of receptor trafﬁcking inside cells,
such as recycling and sorting, i.e., the process by which receptors and ligands are
either targeted for intracellular degradation or recycled to the surface for successive
rounds of trafﬁcking [20].
There is a considerable amount of literature about detailed mechanistic
descriptions of receptor trafﬁcking systems in the systems biology literature (see,
e.g., [5, 21] and references therein). Based on these receptor trafﬁcking systems, our
approach is to build a general detailed mechanistic model of RME that takes into
account the most relevant kinetic processes of drug binding and receptor trafﬁcking
inside the cell. Detailed models derived from the underlying biochemical reaction
network have the advantage of a mechanistic interpretation of the kinetic processes
and estimated parameters. In [22], a cell-level model of the cytokine granulocyte
colony-stimulating factor (G-CSF) and its receptor was incorporated into a
pharmacokinetic/pharmacodynamic model to allow for analyzing the life span
and potency of the ligand in vivo. However, often these advantages come along with
the disadvantage of containing more parameters which, e.g., in population PK
analysis of clinal trials may result in poorer performance in the model selection
process, since models containing more parameters are usually penalized by the
corresponding model selection criteria.
The objective of this article is to develop a framework for RME that is
speciﬁcally tailored to the needs in PK analysis of clinical trials by bridging the
points of view in pharmacokinetics and systems biology. The aims are (i) to develop
a detailed model that takes into account the most relevant processes in relation to
receptor trafﬁcking; (ii) to derive reduced models of RME which retain a
mechanistic interpretation and are deﬁned in terms of a few parameters only, (iii) to
offer guidance as to when use them, and (iv) to analyze the impact of the different
processes on the extent of nonlinearity. While our approach applies to many
receptor systems in general, we will use the epidermal growth factor receptor
(EGFR) signalling pathway to illustrate the approach. The EGFR system has been
intensively studied over the past 20 years and is one of the most important pathways
for cell growth and proliferation as well as angiogenesis and metastasis [23]. The
EGFR system comprises a tyrosine kinase receptor, which is activated by a variety
of ligands such as the epidermal growth factor (EGF) or the transforming growth
factor-a (TGF-a)[ 24–26]. Mathematical modelling of the EGFR system has proven
to be useful for both, measurement of rate constants [27] as well as to elucidate the
effects of receptor trafﬁcking as an input to downstream signalling cascades [21,
28]. From a therapeutic point of view, the EGFR system has shown to be a
promising target in cancer therapy [29, 30]. Several agents, including therapeutic
proteins such as monoclonal antibodies (mAbs), have been developed to speciﬁcally
target the EGFR with some already approved for drug treatment [31–33].
J Pharmacokinet Pharmacodyn (2009) 36:239–260 241
123Theoretical
Throughout the article, the term ’ligand’ refers to both a physiological ligand as well
as an exogenous drug ligand.
Detailed model of RME (Model A)
We propose the following detailed model of RME of a ligand as schematically
represented in Fig. 1: the ligand Lex is present in the extracellular space. The ligand
reversibly binds to free receptor Rm at the cell membrane with association rate
constant kon to form the ligand–receptor complex RLm that dissociates with rate
constant koff. The complex is internalized with the rate constant kinterRL forming an
endosome. The internalized ligand–receptor complex RLi is either recycled to the
membrane with the rate constant krecyRL, degraded with the rate constant kdegRL to
RLdeg, or dissociates with the rate constant kbreak. The dissociation results in the
subsequent degradation of the ligand Ldeg and the availability of the free receptor Ri
inside the cell. Free intracellular receptor Ri is recycled to the membrane with the
rate constant krecyR and free membrane receptor Rm is internalized with the rate
constant kinterR. Inside the cell, the receptor Ri is produced with the rate ksynth and
degraded with the rate constant kdegR.
Based on the law of mass action, the rates of change for the various molecular
species are given by the following system of ordinary differential equations (ODEs):
V
Lex
Rm +
kon
koff
kinterRL
krecyRL
kbreak
krecyR kinterR
RLm
RLi
Ldeg
Ri
kdegR
ksynth
kdegRL
RLdeg
Fig. 1 Schematic representation of the detailed model of receptor mediated endocytosis. See text for
description
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123dLex=dt ¼ koff   RLm   kon=ðVcNAÞ Rm   Lex ð1Þ
dRm=dt ¼ koff   RLm   kon=ðVcNAÞ Rm   Lex þ krecyR   Ri   kinterR   Rm ð2Þ
dRLm=dt ¼ kon=ðVcNAÞ Rm   Lex   koff   RLm   kinterRL   RLm þ krecyRL   RLi ð3Þ
dRLi=dt ¼ kinterRL   RLm   kbreak   RLi   krecyRL   RLi   kdegRL   RLi ð4Þ
dRi=dt ¼ kinterR   Rm   krecyR   Ri þ kbreak   RLi   kdegR   Ri þ ksynth ð5Þ
where NA is Avogadro’s number and Vc is the volume of extracellular space per cell.
In the above equations, all variables are expressed in number of molecules. All
parameters are ﬁrst-order rate constants in units [1/time] except for ksynth, which is a
zero-order rate constant in units [molecules/time], and kon which is a second-order
rate constant in units [1/(concentration 9 time)]. The factor 1/(VcNA) ensures
conversion of units from molar concentration to number of molecules. With respect
to the receptor, the above equations comprise the following three overall processes
(cf. Fig. 1): (1) synthesis and degradation; (2) distribution of the different receptor
species within and between the cytoplasm and the cell membrane; and (3) ligand–
receptor interaction. With respect to the ligand, its disposition processes consist of
the three overall processes: (i) binding to the receptor; (ii) internalization of the
ligand–receptor complex; and (iii) intracellular degradation.
Reduced models of RME
One objective of this study is to derive and analyze reduced models of RME that
capture the impact of receptor dynamics on the distribution and elimination of a
ligand and that still allow for a mechanistic interpretation. While during short time
intervals the transient redistribution processes between the different receptor species
Rm, RLm, RLi and Ri may be of interest, these are usually assumed to be negligible on
time scales of interest in pharmacokinetics. Therefore, our approach to reduce the
detailed RME model will be based on the assumption that the receptor species Rm,
RLm, RLi and Ri are in quasi-steady state. In order to ﬁnally derive reduced models of
RME, it is necessary to make an additional assumption on the time-scale of receptor
synthesis and degradation. We distinguish the following two scenarios: (1) the time
scale of receptor synthesis and degradation is slow in comparison to the time scale of
ligand disposition. In this case, we formally set ksynth = kdegR = kdegRL = 0. As a
consequence, the total number of receptors in the system remains constant. Or, (2)
the time scale of receptor synthesis and degradation is fast, i.e., comparable to the
redistribution processes of the different receptor species. Both scenarios will be used
in the following to establish a link between the reduced and the detailed model.
Reduced model of saturable distribution into the receptor system and linear
degradation (Model B)
The idea in deriving a reduced model of RME is to use the quasi-steady state
assumption for the receptor system (RS). This transforms the differential equations
(2)–(5) into algebraic equations for Rm, RLm, RLi, Ri. For a given number of
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This allows us to compute the total number of ligand molecules in the receptor
system LRS = RLm ? RLi as a function of the extracellular number of ligands Lex.
Based on LRS, the quasi-steady state number of intracellular ligand–receptor
complexes RLi can be computed, which determines the extent of elimination.
Model B (see Fig. 2) describes the evolution of the total number of ligands
Ltot = Lex ? LRS in form of the following ODE:
dLtot=dt ¼  kdegLRS with ð6Þ
LRS ¼
BmaxLex
KM þ Lex
ð7Þ
Lex ¼
1
2
Ltot   Bmax   KM þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ ﬃ
Ltot   Bmax   KM ðÞ
2þ4KMLtot
q   
: ð8Þ
The equations comprise three parameters: the maximal ligand binding capacity Bmax
of the receptor system (in units molecules), the number of extracellular ligand
molecules corresponding to a half-maximal binding capacity KM (in units
molecules), and the degradation rate kdeg (in units 1/time). In this reduced model
the combination of saturable distribution and linear degradation results in the overall
saturable elimination of the ligand.
For the two scenarios of slow or fast receptor synthesis and degradation, the
functional relation between the parameters Bmax, KM and kdeg and the parameters of
the detailed model of RME can be established. In the case of slow receptor synthesis
and degradation, it is
Bmax ¼ R0  
kbreak þ krecyRL þ kinterRL
kbreak þ kinterRL þ krecyRL þ kinterRL   kbreak=krecyR
ð9Þ
KM ¼ KD  
VcNA   kbreak 1 þ kinterRL
koff þ
krecyRL
kbreak
  
kbreak þ kinterRL þ krecyRL þ kinterRL   kbreak=krecyR
ð10Þ
kdeg ¼
kbreak   kinterRL
kinterRL þ kbreak þ krecyRL
; ð11Þ
where R0 is the total number of receptors and KD = koff/kon denotes the dissociation
constant of the ligand–receptor complex. In the case of fast receptor synthesis and
degradation, the relation between the parameters is
Bmax ¼
ksynth
kdegR
 
krecyR  ð krecyRL þ klyso þ kinterRLÞ
kinterRL  ð klyso þ krecyR   kdegRL=kdegRÞ
ð12Þ
KM ¼ KD  
VcNA   kinterR  ð krecyRL þ klyso þ kinterRL   klyso=koffÞ
kinterRL  ð klyso þ krecyR   kdegRL=kdegRÞ
ð13Þ
kdeg ¼
klyso   kinterRL
kinterRL þ klyso þ krecyRL
; ð14Þ
with klyso = kbreak ? kdegRL.
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The proposed Model C (see Fig. 2) is a further reduction of Model B. It is based on
the additional assumption that the amount of ligand distributed into the receptor
system is negligible in comparison to the total amount of ligand molecules, i.e.,
Ltot = Lex ? LRS & Lex. More formally, Model C can be derived from Model B
under the assumption
Bmax
KM þ Lex
  1; ð15Þ
which implies LRS   1 and thus Ltot & Lex from Eq. 7. Substituting Lex by Ltot
in Eq. 7 and LRS into Eq. 6 yields the ODE for the total number of ligand
molecules:
dLtot=dt ¼ 
VmaxLtot
KM þ Ltot
: ð16Þ
The model comprises two parameters: the maximal elimination rate of ligand
molecules Vmax (in units molecules/time) and the number of ligand molecules KM,a t
which the elimination rate is half-maximal. Exploiting the relation
Vmax ¼ kdeg   Bmax; ð17Þ
we obtain the functional relations between Vmax and the parameters of the detailed
model of RME (Model A). In the case of slow receptor synthesis and degradation,
the functional relationship is given by
Vmax ¼ R0  
kbreak   kinterRL
kbreak þ kinterRL þ krecyRL þ kinterRL   kbreak=krecyR
ð18Þ
and KM is deﬁned as in Eq. 10. In the case of fast receptor synthesis and degradation,
it is
Lex
Rm +
kon
koff
kinterRL
krecyRL
kbreak
krecyR kinterR
RLm
RLi
Ldeg
Ri
kdegR
ksynth
kdegRL
RLdeg
Rm
Ltot
Ldeg
Ldeg
Lex
kdeg
Bmax
KM
Vmax
KM
LRS
Fig. 2 Models of receptor mediated endocytosis of different resolution: Detailed model (Model A),
reduced model of saturable distribution into the receptor system with linear degradation (Model B), and
reduced model of saturable degradation (Model C). See text for details
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ksynth
kdegR
 
klyso   krecyR
klyso þ krecyR   kdegRL=kdegR
ð19Þ
and KM is deﬁned as in Eq. 13.
Integration of RME into compartmental PK models
In order to facilitate the transfer of reduced models of RME into compartmental
PK models underlying PK data analysis and for use in the example of
therapeutic protein receptor interaction, we explicitly state the system of ODEs
for a two-compartment PK model. The model comprises a central compartment
(volume V1 (in units volume) and ligand concentration C1 (in units mass/
volume)) from which linear elimination CLlin (in units volume/time) takes place
and a peripheral compartment (volume V2 and total ligand concentration C2),
where saturable elimination via receptor mediated endocytosis CLRS takes place
(see Fig. 3). In the peripheral compartment, we further distinguish between the
concentration CRS within the receptor system and the extracellular concentration
Cex. The inter-compartmental transfer ﬂows are denoted by q12 and q21 (in units
volume/time).
As in this article we are interested in how to represent RME in PK models, the
below mentioned system of ODEs based on the reduced Models B and C represent
the proposed structural PK model that can be used for parameter estimation in PK
data analysis of nonclinical and clinical trials. The parameter values are determined
by performing a ﬁt of the model to the speciﬁc in vivo data. Alternatively, the model
might be used to scale-up in vitro derived RME parameter values to the in vivo
situation (see also Discussion).
If Model B is used to describe the elimination by RME, the system of ODEs is
+
kon
koff RLm
C2
Vmax
KM
C1 Cllin
R +
Cex
CLRS
Bmax, KM
CRS
q12 q21
C1 Cllin
q12 q21
V1
V2
V1
V2
Fig. 3 Two two-compartment models with linear clearance from the central compartment and RME
based on Model B (left) and Model C (right) in the peripheral compartment
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V2   dC2=dt ¼ q12   C1   q21   Cex   CLRS   CRS; with ð21Þ
CRS ¼
Bmax   Cex
KM þ Cex
ð22Þ
Cex ¼
1
2
C2   Bmax   KM þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
C2   Bmax   KM ðÞ
2þ4KMC2
q   
; ð23Þ
where dosing denotes a mass inﬂow (in units mass/time) of, e.g., an i.v. infusion
over a given time. The parameter Bmax denotes the total maximal ligand binding
capacity in mass per volume or mol per volume, KM denotes the concentration at
which the binding capacity is half-maximal, CLlin and CLRS denote the total
elimination capacities (in units volume/time) in the central and peripheral
compartment, respectively. In terms of parameter estimation, the PK model
contains eight parameters: V1, V2, q12, q21,C L lin,C L RS, Bmax and KM, plus
additional variables relating to dosing.
If Model C is used to describe the elimination by RME, the system of ODEs is
V1   dC1=dt ¼ q21   C2   q12   C1   CLlin   C1 þ dosing ð24Þ
V2   dC2=dt ¼ q12   C1   q21   C2  
Vmax   C2
KM þ C2
; ð25Þ
where Vmax denotes the total maximal elimination (in units mass/time), and all
remaining parameters are deﬁned as above. In terms of parameter estimation, the PK
model contains seven parameters: V1, V2, q12, q21,C L lin, Vmax and KM, in addition to
the parameters relating to dosing.
Nonlinear PK caused by RME
In this section, we investigate the extent of nonlinearity in the context of the
Michaelis–Menten model deﬁned in Eqs. 24 and 25. We aim to examine the effect
of drug and cell properties on the nonlinearity of the pharmacokinetics, e.g.,
different drug afﬁnities to the receptor (different kon and koff values) or different
rates of internalization and recycling of the drug in different cells.
In the chosen setting of the two-compartment PK model (cf. Eqs. 24 and 25, the
total clearance CLtot is given by
CLtot ¼ CLlin þ CLRS ¼ CLlin þ
Vmax
KM þ C
; ð26Þ
where C denotes the relevant ligand concentration in the RME compartment (e.g.,
C2 in Eq. 25). While the linear clearance is constant, the clearance attributed to
RME varies between Vmax/KM for small ligand concentrations and 0 for high ligand
concentrations. Therefore, we consider the quotient Vmax/KM as a measure of the
extent of nonlinearity, i.e., the increase in total clearance for small ligand
concentrations.
In order to jointly analyze the slow and the fast receptor synthesis and
degradation scenario, we set
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ksynth
kdegR
  1 þ
kinterR
krecyR
  
ð27Þ
and replace the quotient ksynth/kdegR in Eq. 19 by R0/(1 ? kinterR/krecyR) according to
Eq. 27. Moreover, we extend the deﬁnition of klyso to the slow scenario by setting
klyso = kbreak in this case (note: for the fast scenario klyso = kbreak ? kdegRL). Then,
the extent of nonlinearity for both, the fast and the slow scenario, is given by
Vmax
KM
¼
R0
VcNA
 
kon
koff
kinterRL 1 þ
krecyRL
klyso
  
þ 1
 
1
1 þ kinterR
krecyR
  
kinterR
krecyR
  
0
@
1
A
p
; ð28Þ
where p = 0 for the slow scenario and p = 1 for the fast scenario. The above
equation allows us to study in detail the inﬂuence of the various parameters on the
extent of nonlinearity.
It can be inferred from Table 1 that ligand-speciﬁc, receptor system-speciﬁc as
well as mixed parameters inﬂuence the extent of nonlinearity of the PK:
nonlinearity increases for higher afﬁnity drugs (kon) and cell types, which have a
higher receptor concentration at the surface of the cell membrane (R0, krecyR) and
faster degradation processes (klyso). In contrast, higher values of koff, krecyRL and
higher kinterR, kdegR will decrease the extent of nonlinearity by resulting in a lower
number of intracellular ligand receptor complexes, free receptor molecules, or a
smaller number of receptor molecules at the cell surface membrane.
In order to more clearly highlight the contribution of the dissociation constant
KD, we also give the following alternative representation of Eq. 28:
Vmax
KM
¼
R0
VcNA
 
1
KD
 
1
1
kinterRL 1 þ
krecyRL
klyso
  
þ 1
koff
 
1
1 þ kinterR
krecyR
  
kinterR
krecyR
  
0
@
1
A
p
: ð29Þ
As can be inferred from the above relation, the extent of nonlinearity can be very
different for ligands with the same dissociation constant KD, but different absolute
values of koff. The difference depends on the relative magnitude of the two terms in
the ﬁrst denominator in Eq. 29, i.e., 1/koff to 1/kinterRL   (1 ? krecyRL/klyso).
Table 1 Contribution of the
different parameters to the
extent of nonlinearity
With increasing value of the
corresponding parameter the
extent of nonlinearity will
increase (:) or decrease (;). For
each parameter, it is indicated
by (RS) or (L) whether it is
related to the receptor system or
the ligand, respectively
Increase of parameter Resulting change in
extent of nonlinearity
R0 : (RS)
krecyR : (RS)
kon : (L)
klyso : (RS & L)
kinterRL : (RS & L)
koff ; (L)
kinterR ; (RS)
krecyRL ; (RS & L)
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In order to simulate Models A, B and C, we numerically solved the corresponding
system of ODE’s with Matlabs built-in ode15s integrator (The Mathworks, Inc.,
Natick/MA, USA, version 7.4). Parameter values for the reduced Models B and C
were derived from those of Model A using the established relations (12)–(14), and
(19) and (13), respectively. Subsequently, numbers of molecules where converted
into concentrations (nM).
The models were compared based on the simulated extracellular drug concen-
tration. The speciﬁc details of the simulation studies are given in the respective
Result section to allow for an easier comparison.
EGFR system with endogenous/physiological ligand
The application of our approach is illustrated using the EGFR system as an example.
The properties of the EGF/EGFR system will be analyzed using experimentally
measured parameters for the degradation of the epidermal growth factor, binding to
the epidermal growth factor receptor and subsequent internalization [20, 34]. The
rate constants of the corresponding reactions are listed in Table 2.
Hendriks et al. [20, 34] explored EGF as ligand to measure rate constants of the
EGFR system. Since receptor is degraded as a consequence of ligand degradation,
we choose the scenario of fast receptor synthesis and degradation for all
investigations, i.e., Eqs. 12–14 and 19. However, not all rate constants of the
herein proposed detailed model of RME were explicitly measured in [20, 34]. Since
EGF is predominantly degraded from the EGF-receptor complex [5] rather than
from the free form, we set kbreak = 0 resulting in klyso = kdegRL = 0. Since the
parameter ksynth was not available in literature, we used the steady state assumption
for the receptor system prior to any ligand administration and the experimentally
measured steady state number of membrane receptor Rm
(SS) [28] to determine ksynth
using the relation ksynth = kdegR   Ri
(SS) with Ri
(SS) = Rm
(SS)   kinterR/krecyR. The initial
number of receptors are Rm(0) = Rm
(SS), Ri(0) = Ri
(SS), and RLm(0) = RLi(0) = 0;
the initial concentration of extracellular ligand is Lex(0) = 40 nM.
Table 2 Parameter values for
the EGF/EGFR system
All parameter values have been
extracted from Hendriks et al.
[20, 34] and Shankaran et al.
[28]. See also section ‘‘RME for
the EGF/EGFR system’’
Parameter Numerical value
kon 5.82 1/(nM h)
koff 14.4 1/h
Rm
(SS) 2 9 10
5 molecules
krecyR 3.84 1/h
kinterR 4.2 1/h
kdegR 0.96 1/h
krecyRL 1.2 1/h
kinterRL 15 1/h
kdegRL 1.2 1/h
Vc 4 9 10
-10 1/cell
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The analysis of drug-EGFR interaction are performed using data from the
monoclonal antibody zalutumumab (2F8), as published by Lammerts van Bueren
et al. [11]. Zalutumumab is a human IgG1 EGFR antibody that potently inhibits
tumor growth in xenograft models and has shown encouraging antitumor results in a
phase I/II clinical trial [35, 36]. We transformed the originally published system of
difference equations [11, Supplement] into the corresponding continuous system of
ordinary differential equations
1 (ODEs):
d
dt
Apl ¼ kipAint   kpiApl   kelApl ð30Þ
d
dt
Aint ¼ kpiApl   kipAint   kb
b BmaxðAint=VintÞ
h
ðAint=VintÞ
h þ Kh
M
  Ab
 !
ð31Þ
d
dt
Ab ¼ kb
b BmaxðAint=VintÞ
h
ðAint=VintÞ
h þ Kh
M
  Ab
 !
  b kdegAb; ð32Þ
where Apl, Aint and Ab represent the amount of therapeutic protein in the plasma,
interstitial and binding compartment, respectively; Vint the interstitial volume, kpi
and kip the rate constants for transfer between the plasma and interstitial
compartment, kb the rate constant for binding to and dissociation from EGFR,
and kel the elimination rate constant. Furthermore, b kdeg denotes the rate constant for
elimination by EGFR internalization and degradation, b Bmax the maximal binding
capacity of the therapeutic protein to EGFR, KM the concentration corresponding to
b Bmax=2, and h the Hill factor. The initial amount of drug Apl(0) and the parameters
are listed in Table 3. The reported value of KM =5lg/ml did not allow us to
reproduce the results in [11, Fig.1A]. Only a value of KM = 0.5 lg/ml exactly
reproduced the in silico data, hence we choose the corrected value for subsequent
analyses. Amounts are converted to concentrations by dividing by the corresponding
volume.
Transforming the system of ODEs (30)–(32) from units [mg/kg] to [mg/ml] by
dividing by the corresponding volumes yields equations for Cpl = Apl/Vpl, Cint =
Aint/Vint, Cb = Ab/Vint, in terms of the following scaled parameters q12 = Vpl   kpi,
q21 = Vint   kip,C L lin ¼ kel   Vpl;Bmax ¼ b Bmax=Vint; CLRS ¼ b kdeg   Vint. The model
(30)–(32)scaledtounits[mg/ml]canbedirectlycomparedtoourPKmodel(20)–(23)
with C1 = Cpl, Cex = Cint and CRS = Cb, parameterized with the scaled parameters
above. We remark that alternatively, our compartmental PK models could have been
stated in units [mg/kg].
1 The originally published equations in [11, Supplement] are identical to a certain discretization of the
system of ODEs (30)–(32). The advantage of stating the system as continuous ODEs is that subsequently
any numerical scheme can be used to solve them, in particular high accuracy ODE solver with adaptive
step size control.
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RME for the EGF/EGFR system: an example for ligand–receptor interaction
For all subsequent in silico studies, the parameter values are stated as given in
section ‘‘EGFR system with endogenous/physiological ligand’’, unless stated
otherwise.
Inﬂuence of receptor system properties on RME
We illustrate the approximation features of the two reduced models for predicting
concentration-time proﬁles of the ligand in comparison to the detailed model based
on the EGF/EGFR system. The initial concentration is Cex(0) = 40 nM. In
Fig. 4(left), the predictions of the extracellular EGF concentration Cex is shown for
the three Models A, B and C. All models result in very similar concentration-time
Table 3 Parameter values used
by Lammerts van Bueren et al.
[11]
KM has been corrected, see text
for details. Vpl represents the
plasma volume
Parameter Numerical value
Vpl 35 ml/kg
Vint 70 ml/kg
b Bmax 2 mg/kg
kip 0.043 1/h
kpi 0.043 1/h
kb 0.069 1/h
kel 0.0055 1/h
b kdeg 0.005 1/h
KM 0.5 lg/ml
Apl(0) 2 and 20 mg/kg
h 1.0
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Fig. 4 Concentration-time proﬁle of the extracellular ligand concentration for the Model A (circles on
blue solid line), Model B (squares on blue dashed line) and Model C (diamonds on red dashed line). Left:
Parameter values used according to Table 2. Right: As in left ﬁgure, but decreasing kdegRL 10-fold
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123proﬁles: Almost instantaneously, the amount of ligand in the RS is in equilibrium.
Due to the high concentration of ligand in comparison to the concentration of
receptor, the RS is saturated and the ligand is eliminated at a constant rate. Between
approximately 40-60 h, the system undergoes a transition from saturated to non-
saturated elimination, which is manifested in the linear decline in the ﬁnal phase (in
the semi-logarithmic representation). For the EGF/EGFR system, the detailed model
of RME is well approximated by Model B and also by Model C, the latter taking
into account only the apparent saturable elimination. Based on the predictions of
Model B, we computed the amount of ligand LRS in the receptor system. In
accordance with Eq. 15, LRS is negligible in comparison to extracellular EGF
concentration (cf. Fig. 5, solid line) while Cex[0.01 nM.
In order to study the impact of LRS on the approximation quality of Model C, we
artiﬁcially decrease kdegRL by a factor of 10. All other parameters of the detailed
Model A, including the initial EGF concentration, are identical. Parameters of
Model B and C have been recalculated according to Eqs. 12–14 and Eqs. 19 and 13,
respectively, resulting in particular in an increased maximal binding capacity Bmax.
The predictions of the concentration-time proﬁle of the extracellular EGF
concentration Cex based on the three Models A, B and C are shown in Fig. 4(right).
While Models A and B give almost identical results, the prediction based on Model
C differs signiﬁcantly. Model C over-predicts the extent of elimination by RME. As
shown in Fig. 5 the over-prediction corresponds to periods in time where the
assumption (15) is violated: While Bmax/(KM ? Cex) is small for both settings up to
time 60 h, it starts to increase thereafter, in particular for the setting corresponding
to Fig. 4(right).
Inﬂuence of different cell types on RME
The detailed model A allows us to analyze the inﬂuence of processes on the overall
disposition of ligand in the extracellular space such as, e.g., the ligand receptor
internalization rate constant kinterRL. Alterations in kinterRL have been observed
experimentally [37, 38] and could be the result of a mutation of the EGF receptor. In
view of Eq. 28 we would expect a decrease in the overall elimination capacity with
decreasing internalization rate constant kinterRL. Figure 6(left) shows the impact of
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Fig. 5 Evolution of the ratio
Bmax/(KM ? Cex) for the two
scenarios shown in Fig. 4 left
(solid line) and right (dashed
line)
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123an altered kinterRL on the concentration-time course of EGF with Cex(0) = 40 nM.
As can be seen, cells with a reduced internalization rate constant kinterRL/4 and
kinterRL/16 show a much lower apparent elimination than the reference cells with the
rate constant kinterRL. The difference in the apparent elimination does not only
depend on the absolute magnitude of change of kinterRL, but more precisely on the
magnitude of change of 1/kinterRL   (1 ? krecyRL/klyso) in relation to 1/koff, as can
been inferred from Eq. 29. Changes in kinterRL will have less impact, if 1/koff is large.
This can be seen in Fig. 6(right), which shows the same situation as in the left
ﬁgure, but with koff decreased by a factor of 100 (we also decreased kon by the same
factor in order to keep KD constant).
RME in the monoclonal antibody/EGFR system: an example for therapeutic
protein–receptor interaction
In this section we will illustrate how our uniﬁed theoretical approach to RME
allows for resolving seemingly contradictory statements about the performance of
empirical models of RME. In [11], Lammerts van Bueren et al. reported about a
preclinical study involving a mAb against EGFR in monkeys and their
subsequent data analysis. They developed a two-compartment pharmacokinetic
model comprising a ﬁrst-order elimination of the mAb from plasma, a binding
compartment (representing EGFR-expressing cells) that equilibrates with the
interstitial compartment, and a saturable internalization and degradation of bound
mAb. For a detailed description of the model and the corresponding parameters
see section ‘‘EGFR system with exogenous/therapeutic protein ligand’’. Lammerts
van Bueren et al. concluded that the observed nonlinear decrease of mAb
concentrations in cynomolgus monkeys could not be explained by a saturable
elimination in terms of a Michaelis–Menten model and proposed an alternative
model, which described the data well. In a different study, the Michaelis–Menten
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Fig. 6 Illustration of the dependence of RME on the rate of internalization using the detailed model of
RME (Model A). Parameter values according to Table 2. Left: concentration-time proﬁles of the
extracellular ligand EGF (Lex) for three different internalization rate constants of the ligand–receptor
complex: kinterRL (solid line), kinterRL/4 (dashed line), kinterRL/16 (dotted line). Right: same as before, but
with decreased association and dissociation rate constants: kon/100 and koff/100, respectively. Note that
KD is identical in the left and right graphics
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123model was reported to successfully describe in vivo data for a monoclonal
antibody [10].
The model proposed in [11] is comparable to the two-compartment model
introduced in the section ‘‘Integration of RME into compartmental PK models’’, Eqs.
20–23. In order to understand the inferences made by Lammerts van Bueren et al.
[11], we simulated their model deﬁned in Eqs. 30–32 and compared the results to the
correspondingly parameterized Models B and C (see Fig. 7, left). Since the
experimental data presented in [11] were not available and since model simulations
and data were reported to be in good agreement, we used the Lammerts van Bueren
model as a surrogate for the experimental data. As in [11], we choose a high and low
initial mAb input of 2 and 20 mg/kg. While the predicted mAb plasma concentra-
tions based on Model B are identical to the prediction based on the Lammerts van
Bueren et al. model, predictions based on Model C deviate signiﬁcantly. A closer
inspection reveals that the assumption Bmax/(KM ? Cex(0))   1 is violated for the
low dose of 2 mg/kg. Consequently, the amount of mAb inside the RS cannot be
neglected and we would expect to see deviations between predictions based on
Models B and C. Hence, the use of a Michaelis–Menten based nonlinear elimination
in the interstitial compartment, which neglects the drug distributed into the receptor
system, leads to an over-prediction of drug elimination by RME (see Fig. 7, left).
The difference between the predictions based on Model B and C should
disappear, if the maximal binding capacity is sufﬁciently decreased. This is shown
in Fig. 7(right), where the binding capacity Bmax has been decreased to one 20th of
its original value.
In summary, the inference made in [11] that a Michaelis–Menten term is not
adequate for modeling the nonlinearity present in the data is valid for the speciﬁc
conditions of their experimental design. However, this cannot be generalized to a
statement about the validity of the Michael-Menten approximation of RME, as can
be seen from Fig. 7(right) and also from the results presented in section ‘‘RME for
the EGF/EGFR system’’.
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Fig. 7 Comparison of model predictions for zalutumumab (2F8) based on the Lammerts van Bueren
et al. model (circles on solid line) and the herein proposed compartment models (20)–(23) (squares on
solid line) and (24)-(25) (diamonds on dotted line). Left: parameterization as given in Table 3. Right:
maximal receptor capacity Bmax decreased to one 20th of the original capacity
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Drugs that demonstrate nonlinear pharmacokinetic behavior at therapeutic concen-
trations often cause difﬁculties in designing dosage regimens and determining
relations between drug concentrations and effects. The theoretical bases and
potential causes of nonlinear/dose-dependent pharmacokinetics are many-fold and
have been extensively reviewed (see [17] and reference therein). Therapeutic
proteins bind with high afﬁnity to speciﬁc targets. For many protein drugs
elimination by RME plays a major role in their elimination from the body [3]. RME
is suspected to be a major source for the nonlinear pharmacokinetic behavior that is
observed in pre-/clinical data of numerous protein drugs [6]. In this article we
theoretically investigated the process of RME on the pharmacokinetics of
therapeutic proteins.
The detailed Model A (see Fig. 1) represents RME for an endogenous compound
in terms of a system of biochemical reactions (1)–(5), including the binding of the
ligand to the receptor, subsequent internalization of the complex and eventually
degradation as well as receptor recycling, degradation and synthesis. Two reduced
models have been derived under the assumption that the redistribution processes
between the receptor species Rm, RLm, Ri and RLi are in quasi-steady-state. For the
EGFR system, this assumption has been shown experimentally [27]. For other
receptor systems, the steady state assumption seems reasonable since intracellular
processes are typically much faster than the time scale of interest in pharmaco-
kinetic studies.
With respect to the pharmacokinetics of therapeutic proteins, two aspects of
RME are of particular importance:
1. Distribution as a consequence of the drug binding to the receptor and
subsequent internalization of the complex; and
2. Elimination as a consequence of endocytosis.
Unfortunately both processes typically cannot be differentiated experimentally in
pharmacokinetics. Model B explicitly takes into account the amount of drug LRS
distributed in the receptor system and the elimination by intracellular degradation,
e.g., lysosomes. While the elimination is a linear process in terms of LRS, the
distribution into the receptor system itself is a saturable process, speciﬁed in terms
of Bmax and KM. Model C is derived from model B by assuming in addition that LRS
is negligible in comparison to the extracellular amount Lex. In view of the above two
sub-processes, this is equivalent to the assumption that the distributional aspect of
RME can be neglected. Notably, even if the distributional aspect is negligible, the
receptor system could still very efﬁciently transport ligand molecules into the cell,
where they are subsequently degraded. This can be explained from Eq. 17. It states
that the maximal elimination rate Vmax is the product of the maximal ligand binding
capacity Bmax and the degradation rate constant kdeg. The maximal elimination rate
Vmax may still be large due to a large kdeg, even if Bmax is small. The latter implies a
negligible amount of ligand LRS within the receptor system. The receptor system
acts as a mechanism that transports ligand molecules into the cell to eventually
degrade them. Whether or not the receptor system also serves as a distribution phase
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the usage of the two reduced models:
Model B: Elimination and distribution of ligand into the receptor system are
important processes to be considered.
Model C: The distribution of ligand into the receptor system can be neglected,
only the elimination process is important, which in this case is non-linear.
Based on Model B and the computable criterion (15) it can easily be checked
whether the condition for the applicability of Model C are fulﬁlled. This has been
demonstrated for the EGF/EGFR system in section ‘‘RME for the EGF/EGFR
system’’, see Figs. 4 and 5.
The reduced models are derived under the quasi-steady state assumption that the
receptor redistribution processes are much faster than the ligand pharmacokinetics.
This assumption is of the same type as the assumption underlying the Michaelis–
Menten model of enzyme reactions, where it is assumed that the complex formation,
dissociation and catalytic transformation are much faster than the transformation of
substrate into product. In order to ﬁnally derive reduced models, we have to make an
additional assumption on the time-scale of receptor synthesis and degradation.
There are three different scenarios: receptor synthesis and degradation is (i) as fast
as receptor redistribution (or faster); (ii) slower than the time scale of ligand
pharmacokinetics; or (iii) at an intermediate time scale, i.e., comparable or faster
than ligand PK but slower than receptor redistribution. The ﬁrst two scenarios
correspond to our fast and slow scenario. Under these assumptions it is possible to
either treat receptor synthesis and degradation the same way as the redistribution
processes (in the fast scenario) or neglect it and treat the total amount of receptor as
a constant (in the slow scenario), since in the latter it would not impact the total
number of receptors on the time scale of interest. In the third scenario, however,
receptor synthesis and degradation would need to be taken into account in terms of
an additional ODE. Unless further assumptions are made, this would require to
consider the full system of Eqs. 1–5—which is not suitable for PK parameter
estimation in clinical trials.
The elimination process of RME is speciﬁed in terms of the parameters Vmax and
KM. Noteworthy, the maximal elimination rate Vmax is independent of the processes
of complex formation (kon) and dissociation (koff) of the receptor-ligand complex.
However, the parameters kon and koff inﬂuence the amount of extracellular ligand
molecules KM, at which the elimination rate is half-maximal.
In Fig. 6, we studied the impact of different internalization rate constants kinterRL
on RME. An altered kinterRL could, e.g., result from a mutation in the EGF receptor,
as it has been observed experimentally [37]. Our analysis in section ‘‘Nonlinear PK
caused by RME’’ shows that the ligand elimination rate is affected by various
processes inside the cell. For example, the elimination rate decreases with
decreasing complex internalization rate constant, but the difference is much less
pronounced for a ligand with decreased association and dissociation rate constants
kon and koff—even though the dissociation constant KD is the same in both scenarios
(see Fig. 6, left vs. right). From the detailed Model A, this phenomenon is
understandable: given a ligand that forms a complex with rate constant kon, once the
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dissociation (speciﬁed in terms of koff) and internalization (speciﬁed in terms of
kinterRL). If, e.g., koff/kinterRL   1 then the complex will predominantly be
internalized. Based on KD alone, this property of receptor systems can not be
observed. The ratio koff/kinterRL has recently been introduced as one of two key
parameters to characterize different cell surface receptor systems (termed the
consumption parameter) [28]. In general, our analysis shows that reduced ligand
elimination from the extracellular space can be due to altered processes inside the
cell other than the velocity of internalization of the complex. The inﬂuences of the
processes can be deduced from Eq. 28 and is summarized in Table 1. The
nonlinearity increases with parameters that accelerate’ the processes of receptor
availability at the surface (R0, krecyR) or that accelerate’ the transport and
intracellular degradation of extracellular ligand (kon, kinterRL, klyso). Counteracting
processes (related to the parameters koff, kinterR, krecyRL) decrease the extent of
nonlinearity.
Target-mediated drug disposition (TMDD) models explicitly account for binding
to a target and potential degradation of the resulting complex [16–18]. Although
originally developed to describe effects of extensive drug target binding in tissues,
TMDD has more recently also gained interest as a model of saturable elimination
mechanisms for speciﬁc peptide and protein drugs, including RME [6, 18, 19].
Between TMDD and the herein presented approach, there are a number of distinct
differences. First, the TMDD approach considers pharmacological target binding as
the key process controlling the complex nonlinear processes. Particular features of
receptor trafﬁcking inside the cell are not taken into account. Second, whenever a
drug molecule is degraded in the TMDD setting, both, a drug and a receptor
molecule are degraded. In the herein presented approach, degradation of the drug
does not necessarily imply degradation of the receptor, since the receptor can be
recycled. This is, e.g., an important characteristics for the ligand TNF-a. Third, in
[16], a reduced model of TMDD is presented based on a equilibrium assumption. In
this reduced TMDD model, the unbound extracellular drug concentration is a
function of the total concentration, the total receptor concentration Rtot and the
equilibrium dissociation constant KD [16, Eq. 11]. In our reduced model B, in
contrast, the extracellular drug concentration is a function of the total concentration,
the maximal receptor binding capacity Bmax and the quasi-steady state parameter
KM (cf. Eq. 8). As a consequence, the models make qualitatively different
predictions. For instance, KM does not only depend on the ratio of koff and kon (i.e.,
KD), but also on the actual magnitude of the two parameters, in addition to the
dependence on receptor systems parameters. This implies that two drugs with the
same KD but different koff values might be impacted by RME very differently. This
has been illustrated in Fig. 6 (compare left and right graphics) and discussed above.
If the reduced models of RME are used as part of structural PK models to
estimate parameters in the course of clinical data analysis, the question arises
whether or not the identiﬁed RME parameters Bmax, KM, kdeg and Vmax allow for a
mechanistic interpretation, e.g., whether Bmax can be interpreted as the maximal
RME ligand binding capacity. This question is tightly linked to the question of
identiﬁability of model parameters, sometimes referred to as the inverse problem.
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(see, e.g., [39, Chap. 5–9]). In general, the identiﬁability of model parameters
depends on the structural model (number of compartments, compartment to which
the RME process is linked, existence of additional routes of elimination, etc.), prior
knowledge of model parameters and the quality of the experimental design [39,
Chap. 5]. To illustrate this, we used the detailed model to generate a set of simulated
data, to which we ﬁtted the reduced Models B and C (data not shown). We found
that for a well-designed experiment (i) the estimated parameters of the reduced
RME models obey the expected relations (12)–(14) and (19); (ii) that Model C will
not result in a good ﬁt, if the condition Bmax/(KM ? Lex)   1 is violated. This was
the case for the in vitro data shown in Fig. 4(left), as well as for the in vivo data
shown in Fig. 7(left), where already the authors in [11] reported that they were not
able to ﬁt a Michaelis–Menten based PK model to the experimental data. However,
if the experimental design is not adequate, then we would expect—in accordance
with the parameter identiﬁability problem [39, Chap. 5–9]—that the above
conditions (i) and/or (ii) are violated. This was the case for the in vitro data shown
in Fig. 4(right), where both Model B and Model C could be ﬁtted to the generated
data based on Model A, although the condition Bmax/(KM ? Lex)   1 was violated
(resulting in deviation of the estimated parameters from the expected parameters of
6-20% for Model B and 500% for Model C). Since the criteria in Eq. 15 has not
been met, the violation of relations in Eqs. 19 and 13 for Model C is in accordance
with our expectations. Furthermore, for the situation corresponding to Fig. 4(right),
the expected relation Vmax = kdeg   Bmax (see Eq. 17) was violated, while it was
satisﬁed for the situation corresponding to Fig. 7(left). These results eventually
motivate the following recommendation:
Consistency check: Use both reduced Models B and C to ﬁt the data and check the
two conditions (15) and (17):
Bmax
KM þ Lex
  1 and Vmax ¼ kdeg   Bmax: ð33Þ
A violation of the conditions might indicate an insufﬁcient experimental design,
and/or insufﬁcient convergence of the ﬁtting algorithm (local minimum).
Different empirical models have been proposed and used to model the nonlinear
pharmacokinetics of therapeutic proteins [7–15]. While, e.g., a Michaelis–Menten
based RME model as part of a PK model allowed for describing data in one PK data
analysis (e.g., [10]), it failed to do so in another (e.g., [11]). Due to lack of a sound
theoretical basis to understand the different performances of empirical models, this
certainly was an unsatisfactory situation. The herein presented analysis gives a
thorough background of RME and a clear rationale as to when the proposed reduced
models are applicable. In addition, the functional relations between the parameters
of the detailed Model A and the reduced Models B and C might also serve as a ﬁrst
step to scale in vitro observations on RME to in vivo predictions of either target
mediated disposition or Michaelis–Menten elimination, dependent upon the
expression level and turnover of the target.
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